New rule: Companies must reveal drug costs in TV ads
By 
Joe Mont2019-05-09T19:51:00
Under a new rule enacted by the Department of Health and Human Services, pharmaceutical companies will soon be required to disclose in television commercials the price of their prescription drugs that cost more than $35 per month.
Related articles
-
ArticleCalifornia climate rules cause uncertainty as CARB delays draft guidance
California has delayed the release of draft greenhouse gas reporting rules for businesses until early 2026, the California Air Resources Board said.
-
PremiumNew EU Data Act may impact companies’ GDPR compliance efforts
New rules that have recently come into effect across the EU will allow for greater transfers of data between companies, though experts fear the changes could conflict with Europe’s strict privacy legislation, which protects personal information.
-
ArticleNine states collaborating on data privacy enforcement across state lines
Nine states are collaborating to write and enforce comprehensive data privacy laws, in an effort to protect consumers across jurisdictions and due to the absence of a broad, federal privacy law.
More from Regulatory Policy
-
News BriefFINTRAC hits British Columbia crypto firm with record $125M penalty for AML failures
Canada’s financial intelligence agency has issued its largest-ever penalties against a cryptocurrency exchange, a fine of $126 million (CA$176.9 million). The agency said the exchange’s compliance failures represented a “severe breach of Canada’s anti–money laundering framework.”
-
ArticleNYDFS to firms: apply cybersecurity rules to third-parties
The New York State Department of Financial Services (NYDFS) wants financial firms to step up their game when it comes to third parties and cybersecurity.
-
ArticleNavigating HHS and FDA’s overhaul of the food and beverage industry
Under the Trump administration, the Department of Health and Human Services and the Food and Drug Administration have been hellbent on eliminating synthetic food dyes from food and beverage products, forcing a jarring and costly overhaul with cascading impacts on the operations of the entire industry.